Synthetica Bio lates to tap generative AI to spur drug discovery innovation

Interest in generative AI has skyrocketed in 2023. While the generative AI market is already substantial, worth $10 billion in 2022 according to Grand View Research, it is set to balloon by a compound annual growth rate (CAGR) of 35.6% from 2023 to 2030.  It’s no wonder that a slew of companies — including Exscientia, Insilico Medicine, Atomwise and BenevolentAI — are eager to tap the technology to expedite drug discovery.

Enter Synthetica Bio

The latest entrant in the generative AI scene is Laguna Beach, California-based Synthetica Bio. The startup aims to explore generative AI and large language models (LLMs) to enable real-time data processing. The company, founded by Simon Arkell and Alex Dickinson, entrepreneurs with a successful track record in companies like the predictive analytics firm Predixion, digital pathology startup Deep Lens, biotech Helixis and the molecular diagnostics firm Chromacode, has formed strategic partnerships to propel its platform de…

Read more
  • 0